Release Notes:  Version 20190808

DateAugust 8, 2019 
AccessTerminology Gateway
Release TypeMaintenance Release

About this maintenance release 

This release includes the Canadian Clinical Drug Data Set files (version 20190808).  

The Editorial Guidelines and the Technical Specification have not been revised with this release. 

The Canadian Clinical Drug Data Set is available for browsing and download via the Infoway Terminology Gateway.  

Supporting general information can be found on Infoway Canadian Clinical Drug Data Set InfoCentral page

General Notes

The following files will be available as full release files within this version:

  • Manufactured Product,
  • Non-proprietary Therapeutic Product,
  • Therapeutic Moiety,
  • Manufactured Product, Non-proprietary Therapeutic Product, Therapeutic Product Relationship,
  • Special Groupings, 
  • Coded Attribute, and
  • Device Non-proprietary Therapeutic Product.

The 'Full" release contains one entry for every concept that has ever been released and new content added for that release.   New content added for a specific release may at times include “Inactive” content.

NOTE:  The “Delta" release which is intended to contain only those concepts that have been added or changed since the previous release will be considered for a future enhancement at a later date.  

This release continues to add additional content from the DPD and includes all of the top 250 moieties and approximately 99% of the DPD content in scope for CCDD.  

The table below provides the number of concepts within each CCDD file for this release.

August 2019 CCDD Files
Number of Concepts
Types of Changes in this release
Therapeutic Moiety Full Release1434

12 additions

6 status change from active to inactive (as a result of related MPs no longer being active)

1 formal name technical correction made (8002103; from "cetrimonium and lidocaine" to "cetrimide and lidocaine" with no change in code)

Non-proprietary Therapeutic Product Full Release4222

83 additions

22 status changes

  • 21 active to inactive
  • 1 active to deprecated (see details below)

44 formal name changes (see technical correction details below)

9 status date changes with no change of status

Manufactured Product Full Release11465

175 additions

Formal name changes made:

  • 15 DPD company changes
  • 2 DPD company name change
  • 4 DPD product with name change and company change
  • 7 DPD product name changes
  • 72 formal name changes as a result of the NTP technical corrections (as specified within the NTP change details and 2 also have company name changes)
  • 4 formal name changes (see MP change details below)

132 status changes from active to inactive

6 status changes from inactive to active

4 status changes from active to deprecated (see MP change details below)

32 status date changes (no change of status)

Manufactured Product, Non-proprietary Therapeutic Product, Therapeutic Moiety Relationship

11458

Includes concept additions and changes as above

Deprecated concepts have been excluded.

Device Non-proprietary Therapeutic Product3no change
Special Groupings1826

1 additional concepts added

Includes concept changes as above

Coded Attributes7

no change


NTP Changes

The following NTP changes occurred:

ntp_code August Release

ntp_formal_name August Release

August StatusComments

ntp_code July Release

ntp_formal_name July Release

July Status
9001902cetrimonium bromide 150 mg per 100 g and lidocaine 5 g per 100 g cutaneous gelDepreccorrection required for dose form and ingredient name9001902cetrimonium bromide 150 mg per 100 g and lidocaine 5 g per 100 g cutaneous gelActive
9014016cetrimide 0.15 % and lidocaine 5 % oromucosal gelActivethis concept is new in August and replaces the deprecated concept of 9001902NANANA

 

Please find the following 44 technical correction type of changes with no change in code as follows: 

ntp_code August Release

ntp_formal_name August Release

Type of Change

ntp_code June Release

ntp_formal_name June Release

9012411cromolyn sodium 1 % nebulizer solution 2 mL unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9012411cromolyn sodium 1 % inhalation solution 2 mL unit dose vial
9013957dornase alfa 2.5 mg per 2.5 mL nebulizer solution unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9013957dornase alfa 2.5 mg per 2.5 mL inhalation solution unit dose vial
9000527ipratropium bromide 250 mcg per mL nebulizer solution 20 mL bottle

Dose form change; "inhalation solution" changed to "nebulizer solution"

9000527ipratropium bromide 250 mcg per mL inhalation solution 20 mL bottle
9000754ipratropium bromide 250 mcg per 1 mL nebulizer solution unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9000754ipratropium bromide 250 mcg per 1 mL inhalation solution unit dose vial
9000756ipratropium bromide 500 mcg per 2 mL nebulizer solution unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9000756ipratropium bromide 500 mcg per 2 mL inhalation solution unit dose vial
9000755ipratropium bromide 250 mcg per 2 mL nebulizer solution unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9000755ipratropium bromide 250 mcg per 2 mL inhalation solution unit dose vial
9012555ipratropium bromide 0.5 mg per 2.5 mL and salbutamol (salbutamol sulfate) 2.5 mg per 2.5 mL nebulizer solution unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9012555ipratropium bromide 0.5 mg per 2.5 mL and salbutamol (salbutamol sulfate) 2.5 mg per 2.5 mL inhalation solution unit dose vial
9012508levofloxacin 240 mg per 2.4 mL nebulizer solution unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9012508levofloxacin 240 mg per 2.4 mL inhalation solution unit dose vial
9000692salbutamol (salbutamol sulfate) 1.25 mg per 2.5 mL nebulizer solution unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9000692salbutamol (salbutamol sulfate) 1.25 mg per 2.5 mL inhalation solution unit dose vial
9000338salbutamol (salbutamol sulfate) 5 mg per mL nebulizer solution 10 mL bottle

Dose form change; "inhalation solution" changed to "nebulizer solution"

9000338salbutamol (salbutamol sulfate) 5 mg per mL inhalation solution 10 mL bottle
9000634salbutamol (salbutamol sulfate) 5 mg per 2.5 mL nebulizer solution unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9000634salbutamol (salbutamol sulfate) 5 mg per 2.5 mL inhalation solution unit dose vial
9000444salbutamol (salbutamol sulfate) 2.5 mg per 2.5 mL nebulizer solution unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9000444salbutamol (salbutamol sulfate) 2.5 mg per 2.5 mL inhalation solution unit dose vial
9012869tobramycin (tobramycin sulfate) 300 mg per 5 mL nebulizer solution unit dose vial

Dose form change; "inhalation solution" changed to "nebulizer solution"

9012869tobramycin (tobramycin sulfate) 300 mg per 5 mL inhalation solution unit dose vial
9012781aztreonam 75 mg per vial powder for nebulizer solution with diluent solutionspelling correction9012781aztreonam 75 mg per vial powder for nebuliser solution with diluent solution
9000732budesonide 0.25 mg per 2 mL nebulizer suspension unit dose vialspelling correction9000732budesonide 0.25 mg per 2 mL nebuliser suspension unit dose vial
9000405budesonide 1 mg per 2 mL nebulizer suspension unit dose vialspelling correction9000405budesonide 1 mg per 2 mL nebuliser suspension unit dose vial
9000404budesonide 0.5 mg per 2 mL nebulizer suspension unit dose vialspelling correction9000404budesonide 0.5 mg per 2 mL nebuliser suspension unit dose vial
9003375methacholine chloride 100 mg per vial powder for nebulizer solutionspelling correction9003375methacholine chloride 100 mg per vial powder for nebuliser solution
9003785methacholine chloride 160 mg per vial powder for nebulizer solutionspelling correction9003785methacholine chloride 160 mg per vial powder for nebuliser solution
9003786methacholine chloride 320 mg per vial powder for nebulizer solutionspelling correction9003786methacholine chloride 320 mg per vial powder for nebuliser solution
9003649methacholine chloride 1280 mg per vial powder for nebulizer solutionspelling correction9003649methacholine chloride 1280 mg per vial powder for nebuliser solution
9004182methacholine chloride 1600 mg per vial powder for nebulizer solutionspelling correction9004182methacholine chloride 1600 mg per vial powder for nebuliser solution
9002980ribavirin 6 g per vial powder for nebulizer solutionspelling correction9002980ribavirin 6 g per vial powder for nebuliser solution
9000906beclomethasone dipropionate 100 mcg per actuation pressurized inhalationspelling correction9000906beclomethasone dipropionate 100 mcg per actuation pressurised inhalation
9000907beclomethasone dipropionate 50 mcg per actuation pressurized inhalationspelling correction9000907beclomethasone dipropionate 50 mcg per actuation pressurised inhalation
9001174ciclesonide 200 mcg per actuation pressurized inhalationspelling correction9001174ciclesonide 200 mcg per actuation pressurised inhalation
9001173ciclesonide 100 mcg per actuation pressurized inhalationspelling correction9001173ciclesonide 100 mcg per actuation pressurised inhalation
9000967fluticasone propionate 125 mcg per actuation pressurized inhalationspelling correction9000967fluticasone propionate 125 mcg per actuation pressurised inhalation
9000968fluticasone propionate 250 mcg per actuation pressurized inhalationspelling correction9000968fluticasone propionate 250 mcg per actuation pressurised inhalation
9000969fluticasone propionate 50 mcg per actuation pressurized inhalationspelling correction9000969fluticasone propionate 50 mcg per actuation pressurised inhalation
9006275fluticasone propionate 125 mcg per actuation and salmeterol (salmeterol xinafoate) 25 mcg per actuation pressurized inhalationspelling correction9006275fluticasone propionate 125 mcg per actuation and salmeterol (salmeterol xinafoate) 25 mcg per actuation pressurised inhalation
9006276fluticasone propionate 250 mcg per actuation and salmeterol (salmeterol xinafoate) 25 mcg per actuation pressurized inhalationspelling correction9006276fluticasone propionate 250 mcg per actuation and salmeterol (salmeterol xinafoate) 25 mcg per actuation pressurised inhalation
9012380formoterol fumarate 5 mcg per actuation and mometasone furoate 100 mcg per actuation pressurized inhalationspelling correction9012380formoterol fumarate 5 mcg per actuation and mometasone furoate 100 mcg per actuation pressurised inhalation
9012381formoterol fumarate 5 mcg per actuation and mometasone furoate 200 mcg per actuation pressurized inhalationspelling correction9012381formoterol fumarate 5 mcg per actuation and mometasone furoate 200 mcg per actuation pressurised inhalation
9001074ipratropium bromide 20 mcg per actuation pressurized inhalationspelling correction9001074ipratropium bromide 20 mcg per actuation pressurised inhalation
9000996salbutamol (salbutamol sulfate) 100 mcg per actuation pressurized inhalationspelling correction9000996salbutamol (salbutamol sulfate) 100 mcg per actuation pressurised inhalation
9013475octreotide (octreotide acetate) 30 mg per vial powder for prolonged-release suspension for injection with diluent solution syringe

Dose form change; "with diluent syringe" has been changed to "with diluent solution syringe"

9013475octreotide (octreotide acetate) 30 mg per vial powder for prolonged-release suspension for injection with diluent syringe
9013470octreotide (octreotide acetate) 10 mg per vial powder for prolonged-release suspension for injection with diluent solution syringeDose form change; "with diluent syringe" has been changed to "with diluent solution syringe"9013470octreotide (octreotide acetate) 10 mg per vial powder for prolonged-release suspension for injection with diluent syringe
9013474octreotide (octreotide acetate) 20 mg per vial powder for prolonged-release suspension for injection with diluent solution syringeDose form change; "with diluent syringe" has been changed to "with diluent solution syringe"9013474octreotide (octreotide acetate) 20 mg per vial powder for prolonged-release suspension for injection with diluent syringe
9013500pasireotide (pasireotide pamoate) 60 mg per vial powder for prolonged-release suspension for injection with diluent solution syringeDose form change; "with diluent syringe" has been changed to "with diluent solution syringe"9013500pasireotide (pasireotide pamoate) 60 mg per vial powder for prolonged-release suspension for injection with diluent syringe
9013499pasireotide (pasireotide pamoate) 40 mg per vial powder for prolonged-release suspension for injection with diluent solution syringeDose form change; "with diluent syringe" has been changed to "with diluent solution syringe"9013499pasireotide (pasireotide pamoate) 40 mg per vial powder for prolonged-release suspension for injection with diluent syringe
9013498pasireotide (pasireotide pamoate) 20 mg per vial powder for prolonged-release suspension for injection with diluent solution syringeDose form change; "with diluent syringe" has been changed to "with diluent solution syringe"9013498pasireotide (pasireotide pamoate) 20 mg per vial powder for prolonged-release suspension for injection with diluent syringe
9001385diclofenac potassium 50 mg per sachet powder for oral solutionDose form change; "per pck powder" has been changed to "per sachet powder"9001385diclofenac potassium 50 mg per pck powder for oral solution
9013240prilocaine hydrochloride 40 mg per mL solution for injection 1.8 mL cartridgeChange from presentation strength to concentration strength to enhance clarity9013240prilocaine hydrochloride 72 mg per 1.8 mL solution for injection cartridge



MP Changes

Please note the following changes 

mp_code August Release

mp_formal_name August Release

August StatusComments

mp_code July Release

mp_formal_name July Release

July Status
02182971METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) PFIZER CANADA ULCDeprecNew vial sizes now available with the existing DIN, therefore new concepts required to differentiate the sizes.02182971METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) PFIZER CANADA ULCActive
77701015METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) PFIZER CANADA ULCActiveNew MP code for existing concept (replaces MP code 02182971)NANANA
02182777METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) PFIZER CANADA ULCDeprecNew vial sizes now available with the existing DIN, therefore new concepts required to differentiate the sizes.02182777METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) PFIZER CANADA ULCActive
77701012METHOTREXATE INJECTION USP WITH PRESERVATIVE (MULTIDOSE VIALS) (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) PFIZER CANADA ULCActiveNew MP code for existing concept (was MP code 02182777)NANANA
       
02474891METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) ACCORD HEALTHCARE INCActiveNew DIN assigned and replaces an existing MP code 77700322 (reassigned DIN)NANANA
77700322METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) ACCORD HEALTHCARE INCDeprecthis concept replaced by 0247489177700322METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) ACCORD HEALTHCARE INCActive
02474735METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) ACCORD HEALTHCARE INCActiveNew DIN assigned and replaces an existing MP code 77700323 (reassigned DIN)77700323METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) ACCORD HEALTHCARE INCDeprec
77700323METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) ACCORD HEALTHCARE INCDeprecThis concept replaced by 02474735NANANA
       
 02182955METHOTREXATE INJECTION USP SINGLE USE VIALS. PRESERVATIVE-FREE (methotrexate (methotrexate sodium) 50 mg per 2 mL solution for injection vial) PFIZER CANADA ULC ActiveFormal Name Change with no change to code; Updated MP formal name (by adding to provide a unique MP description DPD descriptor) 02182955METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 50 mg per 2 mL solution for injection vial) PFIZER CANADA ULCActive
02458640LIXIANA (edoxaban (edoxaban tosylate monohydrate) 15 mg oral tablet) SERVIER CANADA INC ActiveFormal Name Change with no change to code;Updated MP formal name (DPD ingredient (hydrate) modified) 02458640LIXIANA (edoxaban (edoxaban tosylate) 15 mg oral tablet) SERVIER CANADA INCActive
02458659LIXIANA (edoxaban (edoxaban tosylate monohydrate) 30 mg oral tablet) SERVIER CANADA INC ActiveFormal Name Change with no change to code; Updated MP formal name (DPD ingredient (hydrate) modified) 02458659LIXIANA (edoxaban (edoxaban tosylate) 30 mg oral tablet) SERVIER CANADA INCActive
02458667LIXIANA (edoxaban (edoxaban tosylate monohydrate) 60 mg oral tablet) SERVIER CANADA INC Active

Formal Name Change with no change to code;Updated MP formal name (DPD ingredient (hydrate) modified)

 02458667LIXIANA (edoxaban (edoxaban tosylate) 60 mg oral tablet) SERVIER CANADA INCActive

Questions, Concerns, Changes

Questions and concerns and suggestions for future consideration are welcomed and should be sent by e-mail at [email protected]

Please note that to access InfoCentral, you must have an Infoway login.  If you have any questions about any of our standards or products, please contact the Infodesk Desk at: 

Toll Free #: 1-877-595-3417 or 416-595-3417 

E-mail: [email protected] 

  • No labels